MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common shares, net of...
$20,908K
Proceeds from sale of
common shares, net of...
$5,232K
Proceeds from employee
options exercised
$1,250K
Proceeds from exercise of
warrants
$319K
Net cash provided by
financing activities
$26,950K
Effect of exchange rate
changes on cash, cash...
$396K
Canceled cashflow
$759K
Net decrease
(increase) in cash, cash...
-$5,030K
Canceled cashflow
$27,346K
Change in fair value of
warrant liability
$35,727K
Loss on impairment of
intangible asset
$14,840K
Stock-based compensation
$4,752K
Accounts payable and
accrued liabilities
$2,271K
Depreciation and
amortization expense
$699K
Issuance costs for common
stock warrant...
$183K
Net income (loss)
attributable to...
$166K
Prepaid expenses and
other current assets
-$46K
Loss on marketable
equity securities, net
-$8K
Maturities of marketable
debt securities
$2,000K
Payment of financed
insurance premium
$684K
Payment of finance lease
liabilities
$59K
Common shares received
and retired for...
$16K
Net cash used in
operating activities
-$18,919K
Canceled cashflow
$58,692K
Net cash used in
investing activities
-$13,457K
Canceled cashflow
$2,000K
Net loss
attributable to lineage
-$63,533K
Deferred revenue
-$6,111K
Deferred income tax
benefit
-$5,280K
Foreign currency
remeasurement
$2,269K
Accounts receivable
$316K
Change in right-of-use
assets and liabilities
-$58K
Accretion of income on
marketable debt securities
$44K
Purchases of marketable
debt securities
$14,935K
Purchase of equipment
$522K
Back
Back
Cash Flow
source: myfinsight.com
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)